Psychedelic Bulletin #136: MindMed Collaborators Share Topline LSD for MDD Results; Oregon Issues Psilocybin Licences; UK Parliament to Discuss Psilocybin Rescheduling

This Week: and lots more… Earlier this month, Matthias Liechti and Felix Mueller shared preliminary results from their Phase 2 LSD for major depressive disorder (MDD) trial.The topline findings report “significant, rapid, durable and beneficial effects” of LSDAccording to MindMed’s press release: As a reminder, MindMed collaborates with the Liechti Lab at University Hospital Basel…


The product has been added to your cart.

Continue shopping View Cart